Trial document

This trial has been registered retrospectively.
drksid header


Trial Description

start of 1:1-Block title


Assessment of drug adherence and knowledge about the disease of patients with type 2 diabetes during inpatient admission to a diabetes clinic within the Rhine-Main region

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Type 2 diabetes (T2D) is a chronic metabolic disease that currently affects about 7.5 million adults at the age of 20 to 79 years in Germany.
In order to reduce the risks of associated diseases and adverse events during diabetes treatment, a long-term and correct use of medication and extensive knowledge of the disease are necessary.
Although it is well known that a well-adjusted blood sugar level reduces the risk of secondary disease, the therapeutic target will often not be achieved. As a result, patients with abnormal blood sugar levels, hypoglycaemia or the effects of secondary diseases are hospitalized.

The aim of the study is to identify risk factors through a structured patient interview which influence the behaviour of patients taking diabetes medication and which might be the cause of their current hospital admission. In a further study, the involvement of a pharmacist during the in-patient hospital stay will be used to develop various solution strategies in order to reduce the identified risk factors.

The participants in the study are people with diabetes over the age of 18 who already suffer of type 2 diabetes, who are taking at least three medications, who have a blood sugar level outside the target range when hospitalized, and who are able to take part in a survey about their diabetes disease and medication by a pharmacist.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The planned cross-sectional study is a pilot study aimed to gain knowledge of the status of adherence of type 2 diabetes patients and their knowledge of their disease.
Therefore, a questionnaire has been developed that considers the different aspects of drug intake, patient health and current diabetes treatment. Afterwards, the recorded drug adherence and patient knowledge will be correlated to both HbA1c and fasting blood glucose levels by which the patient was admitted to hospital.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:


end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00015850
  •   2019/04/24
  •   [---]*
  •   yes
  •   Approved
  •   FF/124/2018, Ethikkommission der Landesärztekammer Hessen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   E11 -  Type 2 diabetes mellitus
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patients with pre-existing type 2 diabetes and derailed blood glucose levels when hospitalized are asked once during their inpatient stay about their drug adherence and their knowledge of the diabetes disease on the basis of a structured questionnaire.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Screening
  •   Single (group)
  •   [---]*
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Drug adherence and patient knowledge about the diabetes disease
Evaluation based on a structured questionnaire. The questionnaire on drug adherence is based on the adherence barriers questionnaire. The questionnaire on patient knowledge is based on the Michigan Diabetes knowledge test. The patient will be interviewed during the inpatient stay.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Blood sugar levels: HbA1c value and fasting blood sugar at inpatient admission

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2019/03/11
  •   60
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Age: >= 18 years,
prescription of at least three medicaments, including at least one oral antidiabetic or Insulin,
HbA1c level at admission >= 6.5% or admission caused by hypoglycaemia,
ability to consent,
ability to understand spoken and written German

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

New onset type 2 diabetes,
Type 1 Diabetes,
homecare patients,
transfer of the patient to another ward,
In case of diagnosis of severe comorbidities, which would significantly reduce life expectancy or require extensive systemic treatment

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Chefarzt Abteilung Endokrinologie und Diabetologie Krankenhaus Sachsenhausen
    • Mr.  Ralf  Jung 
    • Schulstraße 31
    • 60594  Frankfurt am Main
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Institut für Pharmakologie, Toxikologie und Klinische PharmazieTechnische Universität Braunschweig
    • Mr.  Prof. Dr.  Stephan  Scherneck 
    • Mendelssohnstr. 1
    • 38106  Braunschweig
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Schwanen Apotheke Offenbach
    • Ms.  Michaela  Pohl 
    • Marktplatz 8
    • 63065  Offenbach
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Schwanen Apotheke Offenbach
    • Marktplatz 8
    • 63065  Offenbach am Main
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2019/08/31
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.